Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics https://www.businesswire.com/news/home/20180501005558/en/
American Thoracic Society (ATS) 2018 International Conference – San Diego, May 18-23, 2018
May 21, 9:15 a.m.-4:15 p.m. PDT – Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver a poster presentation titled, “Targeting αENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis.” In this presentation, Dr. Bush will present new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, targeting the epithelial sodium channel alpha subunit (αENaC) for the treatment of cystic fibrosis. |